Chemokine receptors, or CCRs, are cytokine receptors that can be found on the surface of some cells and interact with specific chemokines. Mammals have 19 different chemokine receptors that have been identified. They are all members of a large protein family known as G protein-coupled receptors because they each have a 7-transmembrane (7TM) structure and couple to G-protein for signal transduction inside of a cell. Chemokine receptors cause an increase in intracellular calcium (Ca2+) ions after interacting with their particular chemokine ligands (calcium signaling).Cell responses result from this, and one of them is the beginning of the chemotaxis process, which directs the cell to the desired area of the organism. The four different subfamilies of chemokines that chemokine receptors bind are grouped into four families: CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors, and XC chemokine receptors. Some chemokine receptors act as entry points for HIV, while others support inflammatory conditions and cancer.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V146927 | Velaprumig | 2988741-17-7 | Velaprumig is a monoclonal antibody that targets human CD99, CCL25, and anti-human Aβ (Aβ-47F). |
|
V93219 | Vicriviroc malate | 541503-81-5 | Vicriviroc (SCH 417690) malate is an oral CCR5 antagonist with IC50 > 10 nM, and also inhibits MIP-1α and RANTES ligand-induced intracellular calcium release with IC50 values of 0.91 nM and 16 nM, respectively. |
|
V146985 | Viscumneoside V | 119016-92-1 | Viscumneoside V is a plant-derived anti-inflammatory agent found in Viscum album var. |
|
V147000 | VLST-002 | VLST-002 is a humanized antibody expressed in CHO cells that targets CCL5/RANTES. | |
|
V115374 | YJC-10592 | 1226894-87-6 | YJC-10592 is an orally effective CCR-2 antagonist. |
|
V86569 | YM-344031 | 671204-98-1 | YM-344031 is an orally active CCR3 antagonist. |
|
V74750 | ZK 756326 | 874911-96-3 | ZK756326 is a non-peptide chemokine receptor agonist (activator) that targets the CC chemokine receptor CCR8. |
|
V28513 | ZK-756326 dihydrochloride | 1780259-94-0 | ZK756326 diHCl is a non-peptide chemokine receptor agonist (activator) that works on the CC chemokine receptor CCR8. |
|
V147367 | ZL-1218 | ZL-1218 is a selective humanized IgG1 antibody that targets CCR8. | |
|
V147368 | ZL-1218 (FUT8-KO) | ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. | |
|
V2026 | Bindarit (AF2838) | 130641-38-2 | Bindarit (also known as AF-2838; AF 2838) is a potent and selective inhibitor of monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8 with anti-inflammatory activity. |
|
V3651 | Vercirnon | 698394-73-9 | Vercirnon (formerly also known as CCX282-B and GSK1605786) is a novel, potent, orally bioavailable, selective antagonist of CCR9 with an IC50 of 10 nM, used in the research of inflammatory bowel diseases. |
|
V51095 | Vercirnon sodium (CCX282-B; GSK-1605786A) | 886214-18-2 | CCR9 antagonist |
|
V3644 | Aplaviroc | 461443-59-4 | Aplaviroc (formerly known as AK-602; GW-873140; ONO-4128; GW873140A; GSK-873140), a SDP (spirodiketopiperazine) derivative, is a CCR5 entry inhibitor with the potential treatment of HIV infection. |
|
V3645 | Aplaviroc HCl | 461023-63-2 | Aplaviroc HCl (GW873140A; ONO-4128; AK-602; GSK 873140) is the hydrochloride salt of Aplaviroc which is a SDP (spirodiketopiperazine) derivative, and a CCR5 entry inhibitor with anti-HIV activity. |
|
V1810 | Maraviroc (UK427857) | 376348-65-1 | Maraviroc (also known as UK-427857)is a potent, selective and non-competitive CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. |
|
V51114 | Maraviroc-d6 | 1033699-22-7 | Maraviroc-d6 is the deuterium labelled form of Maraviroc. |
|
V4675 | Vicriviroc maleate (SCH-417690 maleate) | 599179-03-0 | Vicriviroc maleate (formerly known as SCH 417690; SCH-D), the maleate salt of vicriviroc, is a novel, potent, selective, orally bioavailable and CNS penetrant antagonist ofCCR5entry inhibitor of HIV-1with aKiof 2.5 nM, and also inhibits HIV-1 in PBMC cells, withIC90s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570). |